Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.

NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel

Open access
Hamaguchi, T, Matsumura, Y, Suzuki, M, Shimizu, K, Goda, R, Nakamura, I, Nakatomi, I, Yokoyama, M, Kataoka, K, Kakizoe, T · 2005 · British Journal of Cancer

Abstract

Paclitaxel (PTX) is one of the most effective anticancer agents. In clinical practice, however, high incidences of adverse reactions of the drug, for example, neurotoxicity, myelosuppression, and allergic reactions, have been reported. NK105, a micellar nanoparticle formulation, was developed to overcome these problems and to enhance the antitumour activity of PTX. Via the self-association process, PTX was incorporated into the inner core of the micelle system by physical entrapment through hydrophobic interactions between the drug and the well-designed block copolymers for PTX. NK105 was compared with free PTX with respect to their in vitro cytotoxicity, in vivo antitumour activity, pharmacokinetics, pharmacodynamics, and neurotoxicity. Consequently, the plasma area under the curve (AUC) values were approximately 90-fold higher for NK105 than for free PTX because the leakage of PTX from normal blood vessels was minimal and its capture by the reticuloendothelial system minimised. Thus, the tumour AUC value was 25-fold higher for NK105 than for free PTX. NK105 showed significantly potent antitumour activity on a human colorectal cancer cell line HT-29 xenograft as compared with PTX (P<0.001) because the enhanced accumulation of the drug in the tumour has occurred, probably followed by its effective and sustained release from micellar nanoparticles. Neurotoxicity was significantly weaker with NK105 than with free PTX. The neurotoxicity of PTX was attenuated by NK105, which was demonstrated by both histopathological (P<0.001) and physiological (P<0.05) methods for the first time. The present study suggests that NK105 warrants a clinical trial for patients with metastatic solid tumours.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.bjc.6602479

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Preparation and characterisation of NK105. (A) The micellar structure of NK105 PTX was incorporated into the inner core of the micelle. (B) The size distribution of NK105 measured by the dynamic light scattering method. The mean diameter of an NK105 micelle was 85 nm.
Figure 1 Preparation and characterisation of NK105. (A) The micellar structure of NK105 PTX was incorporated into the inner core of the micelle. (B) The size distribution of NK105 measured by the dynamic light scattering method. The mean diameter of an NK105 micelle was 85 nm.CC BY · PubMed Central
Figure 2 Plasma and tumour concentrations of PTX after single i.v. administration of NK105 or PTX to Colon 26-bearing CDF1 mice. Plasma (A) and tumour (B) concentrations of PTX after NK105 administration at a PTX-equivalent dose of 50 mg kg−1 (•), NK105 at a PTX-equivalent dose of 100 mg kg−1 (▴), PTX 50 mg kg−1 (○) and PTX 100 mg kg−1 (▵).
Figure 2 Plasma and tumour concentrations of PTX after single i.v. administration of NK105 or PTX to Colon 26-bearing CDF1 mice. Plasma (A) and tumour (B) concentrations of PTX after NK105 administration at a PTX-equivalent dose of 50 mg kg−1 (•), NK105 at a PTX-equivalent dose of 100 mg kg−1 (▴), PTX 50 mg kg−1 (○) and PTX 100 mg kg−1 (▵).CC BY · PubMed Central
Figure 3 Relative changes in HT-29 tumour growth rates in nude mice. (A) Effects of PTX (open symbols) and NK105 (closed symbols). PTX and NK105 were injected i.v. once weekly for 3 weeks at PTX-equivalent doses of 25 mg kg−1 (□, ▪), 50 mg kg−1 (▵, ▴), and 100 mg kg−1 (○, •), respectively. Saline was injected to control animals (•). (B) Changes in relative body weight. Data were derived from the same mice as those used for the present study.
Figure 3 Relative changes in HT-29 tumour growth rates in nude mice. (A) Effects of PTX (open symbols) and NK105 (closed symbols). PTX and NK105 were injected i.v. once weekly for 3 weeks at PTX-equivalent doses of 25 mg kg−1 (□, ▪), 50 mg kg−1 (▵, ▴), and 100 mg kg−1 (○, •), respectively. Saline was injected to control animals (•). (B) Changes in relative body weight. Data were derived from the same mice as those used for the present study.CC BY · PubMed Central
Figure 4 Incorporation of PTX into polymeric micelles diminishes neurotoxicity. (A) Effects of PTX or NK105 on the amplitude of rat caudal sensory nerve action potentials as examined 5 days after weekly injections for 6 weeks. Rats (n=14) were injected with NK105 (▪) or PTX (□) at a PTX-equivalent dose of 7.5 mg kg−1. Glucose (5%) was also injected in the same manner to animals in the control group (▪). *P<0.05, **P<0.01. (B) Histopathological changes in the sciatic nerve of rats. Degenerating myelinated nerve fibres (arrow) were examined in the longitudinal section of the sciatic nerve (H & E) 5 days after weekly injections for 6 weeks with 5% glucose (a), PTX (b), and NK105 (c) at a PTX-equivalent dose of 7.5 mg kg−1. Magnification, × 100 (upper) and × 400 (lower). (C) Incidences of degenerating myelinated nerve fibres in rats treated with PTX or NK105. NK105 or PTX was administered i.v. at a weekly dose of 7.5 mg kg−1 for 6 consecutive weeks to female rats. The degenerating myelinated fibre score was defined as follows: −, no degenerative changes; +/−, very slight degree of the degenerative changes (scattered, single fibres affected); +, slight degree of degenerative changes (scattered small groups of degenerative myelinated fibres); ++, moderate degree of degenerative changes (disseminated degenerative myelinated fibres); +++, marked degree of degenerative changes (confluent groups of affected fibres). aP<0.001 vs vehicle-treated animals. bP<0.001 vs PTX-treated animals.
Figure 4 Incorporation of PTX into polymeric micelles diminishes neurotoxicity. (A) Effects of PTX or NK105 on the amplitude of rat caudal sensory nerve action potentials as examined 5 days after weekly injections for 6 weeks. Rats (n=14) were injected with NK105 (▪) or PTX (□) at a PTX-equivalent dose of 7.5 mg kg−1. Glucose (5%) was also injected in the same manner to animals in the control group (▪). *P<0.05, **P<0.01. (B) Histopathological changes in the sciatic nerve of rats. Degenerating myelinated nerve fibres (arrow) were examined in the longitudinal section of the sciatic nerve (H & E) 5 days after weekly injections for 6 weeks with 5% glucose (a), PTX (b), and NK105 (c) at a PTX-equivalent dose of 7.5 mg kg−1. Magnification, × 100 (upper) and × 400 (lower). (C) Incidences of degenerating myelinated nerve fibres in rats treated with PTX or NK105. NK105 or PTX was administered i.v. at a weekly dose of 7.5 mg kg−1 for 6 consecutive weeks to female rats. The degenerating myelinated fibre score was defined as follows: −, no degenerative changes; +/−, very slight degree of the degenerative changes (scattered, single fibres affected); +, slight degree of degenerative changes (scattered small groups of degenerative myelinated fibres); ++, moderate degree of degenerative changes (disseminated degenerative myelinated fibres); +++, marked degree of degenerative changes (confluent groups of affected fibres). aP<0.001 vs vehicle-treated animals. bP<0.001 vs PTX-treated animals.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Research works printed but not linked: 1

  1. Hamaguchi T, Matsumura Y, Shirao Y, Shimada Y, Yamada Y, Muro Y, Okusaka T, Ueno H, Ikeda M, Watanabe N (2003) Phase I study of novel drug delivery system, NK911, a polymer micelle encapsulated doxorubicin. Proc Am Soc Clin Oncol 22: 571

Cited by

See all 565

Metadata

Authors
Hamaguchi, T., Matsumura, Y., Suzuki, M., Shimizu, K., Goda, R., Nakamura, I., Nakatomi, I., Yokoyama, M., Kataoka, K., & Kakizoe, T.
Affiliations
  • National Cancer Centre Japan (JP)
  • Nippon Kayaku (Japan) (JP)
  • NanoCarrier (Japan) (JP)
  • Kanagawa Academy of Science and Technology (JP)
  • The University of Tokyo (JP)
Corresponding author
Matsumura, Y
Venue
British Journal of Cancer
Published
2005-03-22
Volume
92
Issue
7
Pages
1240-1246
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W2112927879
Cited by
565
References
23
Citations by year
2026: 12 · 2025: 17 · 2024: 18 · 2023: 18 · 2022: 23 · 2021: 23 · 2020: 29 · 2019: 21 · 2018: 27 · 2017: 36 · 2016: 41 · 2015: 50 · 2014: 40 · 2013: 29 · 2012: 33
FWCI
10.73
Type
journal article
Language
en
Open access
Locations
  • British Journal of Cancer (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Keywords
paclitaxel, micellar nanoparticles, nanoparticle drug delivery, neurotoxicity, antitumour activity, pharmacokinetics, pharmacodynamics, block copolymer micelles, colorectal cancer, HT-29 xenograft, drug leakage, sustained drug release, metastatic solid tumors
MeSH terms
Animals, Antineoplastic Agents, Phytogenic, Chemistry, Pharmaceutical, Colonic Neoplasms, Humans, Nervous System, Transplantation, Heterologous, Paclitaxel, Area Under Curve, Nanostructures, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. https://app.cochat.ai/papers/10.1038/sj.bjc.6602479
The paper
Hamaguchi, T., Matsumura, Y., Suzuki, M., Shimizu, K., Goda, R., Nakamura, I., Nakatomi, I., Yokoyama, M., Kataoka, K., & Kakizoe, T. (2005). NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6602479

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.